AstraZeneca expands deal with ImaginAb; Ovid posts promising data on Takeda-partnered seizure drug
→ On a day when AstraZeneca issued a flurry of updates on three of its blockbuster therapies, the British drugmaker also
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
